DK1008588T3 - 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel - Google Patents
11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddelInfo
- Publication number
- DK1008588T3 DK1008588T3 DK98901576T DK98901576T DK1008588T3 DK 1008588 T3 DK1008588 T3 DK 1008588T3 DK 98901576 T DK98901576 T DK 98901576T DK 98901576 T DK98901576 T DK 98901576T DK 1008588 T3 DK1008588 T3 DK 1008588T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives
- processes
- preparation
- active ingredient
- pharmaceutical compositions
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 101150053131 PTGER3 gene Proteins 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4157197 | 1997-02-10 | ||
| PCT/JP1998/000544 WO1998034916A1 (fr) | 1997-02-10 | 1998-02-10 | Derives de 11,15-o-dialkylprostaglandine e, leur procede de production, et medicaments renfermant ceux-ci comme principe actif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1008588T3 true DK1008588T3 (da) | 2003-07-28 |
Family
ID=12612138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98901576T DK1008588T3 (da) | 1997-02-10 | 1998-02-10 | 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6288119B1 (da) |
| EP (1) | EP1008588B1 (da) |
| JP (1) | JP4044967B2 (da) |
| KR (1) | KR20000070903A (da) |
| AT (1) | ATE237587T1 (da) |
| DE (1) | DE69813571T2 (da) |
| DK (1) | DK1008588T3 (da) |
| ES (1) | ES2196527T3 (da) |
| PT (1) | PT1008588E (da) |
| WO (1) | WO1998034916A1 (da) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
| US6894175B1 (en) | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| EP1563845A4 (en) * | 2002-10-10 | 2008-02-20 | Univ Kyoto | REMEDIES FOR ALLERGIC DISEASES |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| WO2004074842A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3) |
| JPWO2004089411A1 (ja) * | 2003-04-03 | 2006-07-06 | 小野薬品工業株式会社 | 脊柱管狭窄症治療剤 |
| WO2005009468A1 (ja) | 2003-07-25 | 2005-02-03 | Ono Pharmaceutical Co., Ltd. | 軟骨関連疾患治療剤 |
| WO2005053707A1 (ja) | 2003-12-05 | 2005-06-16 | Ono Pharmaceutical Co., Ltd. | 馬尾神経組織血流増加剤 |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| MY145694A (en) * | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| KR101320810B1 (ko) * | 2005-06-03 | 2013-10-21 | 오노 야꾸힝 고교 가부시키가이샤 | 신경 재생 및/또는 보호제 |
| EP1951701A2 (en) | 2005-08-09 | 2008-08-06 | Asterand Uk Limited | Ep2 receptor agonists |
| LT1976828T (lt) | 2005-12-29 | 2017-04-25 | Celtaxsys, Inc. | Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai |
| US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| CN103271906A (zh) | 2006-10-12 | 2013-09-04 | 泽农医药公司 | 螺-吲哚酮化合物作为治疗剂的用途 |
| WO2009065081A2 (en) | 2007-11-14 | 2009-05-22 | Cayman Chemical Company | Prostaglandin e1 and e2 analogs for the treatment of various medical conditions |
| NZ592275A (en) | 2008-10-17 | 2013-04-26 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010045197A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| EP2441760B1 (en) | 2009-06-10 | 2013-11-20 | ONO Pharmaceutical Co., Ltd. | Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011047173A2 (en) | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MY165579A (en) | 2009-10-14 | 2018-04-05 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| CN105726531A (zh) | 2010-02-26 | 2016-07-06 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| CA2869547A1 (en) | 2012-04-12 | 2013-10-17 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| EP2891651B1 (en) | 2012-08-31 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Amine salt and crystals thereof |
| AU2014240042C1 (en) | 2013-03-14 | 2019-09-05 | Celltaxis, Llc | Inhibitors of leukotriene A4 hydrolase |
| EP2818484A1 (en) | 2013-06-28 | 2014-12-31 | Universitat Autònoma de Barcelona | Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| EP3551608A1 (en) | 2016-12-09 | 2019-10-16 | Celtaxsys Inc. | Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase |
| CA3045950A1 (en) | 2016-12-09 | 2018-06-14 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CA3045954A1 (en) | 2016-12-09 | 2018-06-14 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835180A (en) * | 1971-05-04 | 1974-09-10 | Upjohn Co | 15 alkoxy pge compounds |
| US3876690A (en) * | 1973-05-11 | 1975-04-08 | American Cyanamid Co | 1-alkoxy-9-keto-prostenoic acid derivatives |
| GB1451798A (en) * | 1973-08-02 | 1976-10-06 | Ici Ltd | Prostanoic acid derivatives |
| US4236027A (en) * | 1977-10-17 | 1980-11-25 | American Cyanamid Company | Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same |
| JPS55115836A (en) * | 1979-03-02 | 1980-09-06 | Toray Ind Inc | Preparation of methyl ether derivative |
| DE3510978A1 (de) * | 1985-03-22 | 1986-09-25 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPH03101622A (ja) * | 1989-09-11 | 1991-04-26 | Green Cross Corp:The | 肝炎予防治療剤 |
-
1998
- 1998-02-10 AT AT98901576T patent/ATE237587T1/de not_active IP Right Cessation
- 1998-02-10 DK DK98901576T patent/DK1008588T3/da active
- 1998-02-10 EP EP98901576A patent/EP1008588B1/en not_active Expired - Lifetime
- 1998-02-10 KR KR1019997007168A patent/KR20000070903A/ko not_active Application Discontinuation
- 1998-02-10 JP JP53414898A patent/JP4044967B2/ja not_active Expired - Lifetime
- 1998-02-10 PT PT98901576T patent/PT1008588E/pt unknown
- 1998-02-10 ES ES98901576T patent/ES2196527T3/es not_active Expired - Lifetime
- 1998-02-10 US US09/355,626 patent/US6288119B1/en not_active Expired - Lifetime
- 1998-02-10 WO PCT/JP1998/000544 patent/WO1998034916A1/ja not_active Application Discontinuation
- 1998-02-10 DE DE69813571T patent/DE69813571T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2196527T3 (es) | 2003-12-16 |
| DE69813571T2 (de) | 2004-02-12 |
| EP1008588B1 (en) | 2003-04-16 |
| EP1008588A4 (en) | 2000-06-14 |
| DE69813571D1 (de) | 2003-05-22 |
| EP1008588A1 (en) | 2000-06-14 |
| US6288119B1 (en) | 2001-09-11 |
| WO1998034916A1 (fr) | 1998-08-13 |
| KR20000070903A (ko) | 2000-11-25 |
| ATE237587T1 (de) | 2003-05-15 |
| JP4044967B2 (ja) | 2008-02-06 |
| PT1008588E (pt) | 2003-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1008588T3 (da) | 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel | |
| BR0108893B1 (pt) | composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. | |
| PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
| NO20034660L (no) | Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater | |
| DK1246809T3 (da) | 5-aryl-1H-1,2,4-triazolforbindelser som inhibitor for cyclooxygenase-2 og farmaceutiske sammensætninger som indeholder dem | |
| PL396946A1 (pl) | Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV | |
| ECSP045104A (es) | Ligandos de los receptores de los cannabinoides | |
| EA199900937A1 (ru) | Фармацевтические композиции, содержащие вориконазол | |
| EP1018514A4 (en) | NF- $ g (k) B INHIBITORS CONTAINING INDANE DERIVATIVES AS ACTIVE INGREDIENT | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| EA200200708A1 (ru) | Производные бензазола и их применение в качестве модуляторов jnk | |
| NO20045042L (no) | 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| ATE316089T1 (de) | Isoindolderivate | |
| IL136100A (en) | Biphenylamidine derivatives and pharmaceutical compositions containing the same | |
| DK0884051T3 (da) | Cancröse metastaseinhibitorer indeholdende uracilderivater | |
| GB0223232D0 (en) | Chemical compounds | |
| BR9807330A (pt) | Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo | |
| NO996284D0 (no) | Nye imidazolinforbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem | |
| DK1179342T3 (da) | Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse | |
| NO20023363L (no) | Kondenserte pyrrolforbindelser, farmasöytiske midler som inneholder dem, og anvendelse derav | |
| NO983217D0 (no) | Terapeutiske anti-astmamidler som inneholder selenforbindeler | |
| GB0223234D0 (en) | Chemical compounds | |
| DK0412015T3 (da) | Hidtil ukendte N-(23-vincristinoyl)- og N-(5-noranhydro-23-vinblastinoyl)-1-aminomethylphosphon- syrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem |